AGENUS INC (AGEN)

Company Profile

Agenus Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Lexington, Massachusetts and currently employs 389 full-time employees. The company went IPO on 2000-02-04. Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. The company is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Company Info

AGENUS INC

3 Forbes Rd

Lexington MASSACHUSETTS 02421

P: 17816744400

CEO: Garo H. Armen

Employees: 389

Website: https://agenusbio.com/